Background: Amphicrine prostate carcinoma (AMPC) is a poorly defined subset of prostate cancer in which cells co-express luminal prostate epithelial and neuroendocrine markers. The optimal treatment strategy is unknown. We sought to further characterize the clinical, histomorphologic, and molecular characteristics of AMPC and to identify areas of potential future treatment investigations.
View Article and Find Full Text PDFIntroduction: A significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor mutations in homologous recombination (HR) repair genes, with some of these mutations associating with increased tumor susceptibility to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapy. While mutations in some HR repair genes (e.g.
View Article and Find Full Text PDFBackground: Optimal utilization of novel therapies for advanced prostate cancer is challenging without a validated surrogate efficacy endpoint. Ongoing trials are using durable undetectable prostate-specific antigen (PSA) levels as a marker of efficacy. The clinical relevance of prolonged undetectable PSA after a short course of androgen deprivation therapy (ADT) is uncertain.
View Article and Find Full Text PDFManually populating a cancer registry from free-text pathology reports is labor intensive and costly. This poster describes a method of automated text extraction to improve the efficiency of this process and reduce cost. FineTooth, a software company, provides an automated service to the Fred Hutchinson Cancer Research Center (FHCRC) to help populate their breast and prostate cancer clinical research database by electronically abstracting over 80 data fields from pathology text reports.
View Article and Find Full Text PDF